Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.63 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.49 |
| ▸ | BCL2 | P10415 | 4/20 | 0.47 |
| ▸ | BECN1 | Q14457 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243401 | 0.95 | CYP17A1 (0.56) | CYP17A1PSMB8NAMPTCD274EPHX2 | |
| SCHEMBL20865536 | 0.90 | CYP17A1 (0.68) | CYP17A1PSMB8NAMPTCD274MAP4K4 | |
| SCHEMBL22461618 | 0.89 | NAMPT (0.65) | CYP17A1NAMPTCD274EPHX2NR1H4 | |
| SCHEMBL22461360 | 0.89 | NAMPT (0.65) | CYP17A1NAMPTCD274EPHX2NR1H4 | |
| Aminobenzoic Acid SCHEMBL6627812 | 0.88 | CYP17A1 (0.50) | CYP17A1PSMB8NAMPTEPHX2NR1H4 | |
| SCHEMBL18570243 | 0.87 | CYP17A1 (0.61) | CYP17A1PSMB8NAMPTCD274MAPT | |
| SCHEMBL14274234 | 0.86 | CYP17A1 (0.59) | CYP17A1PSMB8NAMPTCD274BCL2 | |
| SCHEMBL3020158 | 0.86 | PTPN11 (0.59) | CYP17A1PSMB8NAMPTCD274EPHX2 | |
| Toluene SCHEMBL27667509 | 0.86 | NAMPT (0.52) | CYP17A1NAMPTEPHX2NR1H4MAPT | |
| SCHEMBL5544961 | 0.86 | CYP17A1 (0.61) | CYP17A1PSMB8NAMPTCD274MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665373-A2 | SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | SYMERES NETHERLANDS B.V. (NL) | 2025-05-08 | — | — | US | disclosed |
| CN-119301105-A | Thiostrepton-based compounds for the treatment of cancer and preparation thereof | RS肿瘤学有限责任公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-01-09 | — | — | US | disclosed |
| EP-4479390-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024173644-A2 | SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2023158679-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158679-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004003561-A9 | PEPTIDE ROD AMPHIPHILES AND SELF-ASSEMBLY OF SAME | UNIV NORTHWESTERN (US) | 2004-08-12 | — | — | WO | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| WO-2004003561-A1 | PEPTIDE ROD AMPHIPHILES AND SELF-ASSEMBLY OF SAME | NORTHWESTERN UNIVERSITY (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030232808-A1 | Sulfonyl derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| CN-1278793-A | Sulfonyl derivatives | DAIICHI SEIYAKU CO (JP) | 2001-01-03 | — | — | CN | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | CYP17A1 946/4885PSMB8 2339/4885NAMPT 4703/4885 |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | CYP17A1 4511/4885PSMB8 3484/4885NAMPT 1635/4885 |
| US-20030232808-A1 | Sulfonyl derivatives | SULT1E1, SULT2A1, SULT1A1 | CYP17A1 1539/4885PSMB8 2976/4885NAMPT 4480/4885 |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | CYP17A1 609/4885PSMB8 2351/4885NAMPT 580/4885 |
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | TYMS, TOP1, TOP2A | CYP17A1 3920/4885PSMB8 4353/4885NAMPT 397/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | CYP17A1 499/4885PSMB8 2450/4885NAMPT 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.